Exagen (XGN)
(Delayed Data from NSDQ)
$2.04 USD
+0.08 (4.08%)
Updated Jun 17, 2024 04:00 PM ET
After-Market: $2.03 -0.01 (-0.49%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum C VGM
Brokerage Reports
Exagen Inc. [XGN]
Reports for Purchase
Showing records 21 - 36 ( 36 total )
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Recovery in Dx Testing with Larger Menu in 2023
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Strong Quarter, Strong Outlook, Momentum Building
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
The Best Type of ''Guide Down''; Building Visibility Warrants Higher Multiple
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Worth More with Less SIMPONI; Diagnostic Sum-of-Parts; Raising Target Price to $33
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Company: Exagen Inc.
Industry: Medical - Products
Molecular Diagnostic Market Improves in 3Q; S-3 Filing Potentially Addresses 70% Valuation Discount
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Initiating Coverage on Life Science Technology, Bioproduction, - Diagnostics
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Initiating Coverage at Overweight; Micro-Cap Discount for Autoimmune Molecular Dx Leader
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Exagen Inc.
Industry: Medical - Products
Initiating Coverage on Life Science Technology, Bioproduction, - Diagnostics
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department